メインコンテンツに移動
News
-
- 31 October, 2024 Management / Finance
- Ono Pharmaceutical Co., Ltd. Announced 2024 Q2 Financial Results
-
- 31 July, 2024 Management / Finance
- Ono Pharmaceutical Co., Ltd. Announced 2024 1Q Financial Results
-
- 09 May, 2024 Company
- Ono Pharmaceutical Co., Ltd. Announced 2023 Full Year Financial Results
-
- 22 March, 2024 Licensing
- Ono Pharmaceutical Co., Ltd. Enters into Comprehensive Drug Discovery Collaboration Agreement with University of Oxford
-
- 14 March, 2024 Licensing
- Ono Pharmaceutical Co., Ltd. Enters into a Collaboration Agreement with Sibylla Biotech to Generate Novel Drug Candidates for Neurological Disorders
-
- 14 February, 2024 Licensing
- Ono Pharmaceutical Co., Ltd. Enters into an Option and Collaboration Agreement with Numab to Develop Multi-specific Antibody NM49
-
- 07 February, 2024 Sustainability
- Ono Pharmaceutical Co., Ltd. Selected as Highest Rating A-List Company by CDP in Two Categories of “Climate Change” and “Water Security” in CDP 2023
-
- 31 January, 2024 Company
- Ono Pharmaceutical Co., Ltd. Announced 2023 3Q Financial Results
-
- 09 January, 2024 Company
- Ono Pharmaceutical Co., Ltd. supports for Disasters Caused by the 2024 Noto Peninsula Earthquake
-
- 20 December, 2023 Licensing
- Ono Pharmaceutical Co., Ltd. Enters into Research Collaboration with UK Dementia Research Institute
-
- 13 December, 2023 Sustainability
- Ono Pharmaceutical Co., Ltd. Selected for the DJSI World Index and DJSI Asia Pacific Index for Four Straight Years
-
- 01 November, 2023 Company
- Ono Pharmaceutical Co., Ltd. Announced 2023 2Q Financial Results
-
- 24 October, 2023 Licensing
- Ono Pharmaceutical Co., Ltd. Enters into a Research Collaboration Agreement with Turbine to Identify and Validate Novel Therapeutic Targets in Oncology
-
- 31 July, 2023 Company
- Ono Pharmaceutical Co., Ltd. Announced 2023 1Q Financial Results
-
- 30 May, 2023 Company
- Announcement of address change
-
- 10 May, 2023 Company
- Ono Pharmaceutical Co., Ltd. Announced 2022 Full Year Financial Results
-
- 23 March, 2023 Licensing
- Ono Pharmaceutical Co., Ltd. Enters into a Drug Discovery Collaboration Agreement with Macomics to Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer
-
- 17 February, 2023 Company
- Ono Pharmaceutical Co., Ltd. Supports for Relief Efforts in the Earthquake in Turkey and Syria
-
- 31 January, 2023 Company
- Ono Pharmaceutical Co., Ltd. Announced 2022 3Q Financial Results
-
- 27 December, 2022 Sustainability
- Ono Pharmaceutical Co., Ltd. Selected for the DJSI World Index and DJSI Asia Pacific Index for Three Straight Years
-
- 27 December, 2022 Sustainability
- Ono Pharmaceutical Co., Ltd. Selected as Highest Rating A-List Company by CDP in Two Categories of “Climate Change” and “Water Security” in CDP 2022
-
- 14 December, 2022 Licensing
- Ono Pharmaceutical Co., Ltd. Enters into a Multi Target R&D Collaboration Agreement with PrecisionLife
-
- 14 November, 2022 Licensing
- Ono Pharmaceutical Co., Ltd. Enters a Drug Discovery Collaboration Agreement with Captor Therapeutics to Develop Small Molecule Protein Degraders for the Treatment of Neurodegenerative Diseases
-
- 01 November, 2022 Licensing
- Ono Pharmaceutical Co., Ltd. Enters a Drug Discovery Collaboration Agreement with Memo Therapeutics to Discover and Develop Antibody Drugs in the Immuno-oncology Field
-
- 31 October, 2022 Company
- Ono Pharmaceutical Co., Ltd. Announced 2022 2Q Financial Results
-
- 01 August, 2022 Company
- Ono Pharmaceutical Co., Ltd. Announced 2022 1Q Financial Results
-
- 11 May, 2022 Company
- Ono Pharmaceutical Co., Ltd. Announced 2021 Full Year Financial Results
-
- 31 January, 2022 Company
- Ono Pharmaceutical Co., Ltd. Announced 2021 3Q Financial Results
-
- 17 January, 2022 Licensing
- Ono Pharmaceutical Co., Ltd. Expands Drug Discovery Collaboration with Neurimmune AG in the Field of Neurodegenerative Diseases
-
- 15 December, 2021 Sustainability
- Ono Pharmaceutical Co., Ltd. Selected as a Highest Rating A-List Company for Both “Climate Change” and “Water Security” in CDP 2021
-
- 01 November, 2021 Company
- Ono Pharmaceutical Co., Ltd. Announced 2021 2Q Financial Results
-
- 06 August, 2021 Licensing
- Ono Pharmaceutical Co., Ltd. Entered into Research Collaboration Agreement with Healx Limited
-
- 30 July, 2021 Company
- Ono Pharmaceutical Co., Ltd. Announced 2021 1Q Financial Results
-
- 11 May, 2021 Company
- Ono Pharmaceutical Co., Ltd. Announced 2020 Full Year Financial Results
-
- 01 February, 2021 Company
- Ono Pharmaceutical Co., Ltd. Announces 2020 3Q Financial Results
-
- 25 December, 2020 Company
- ONO PHARMA UK LTD. launches a new website.(304KB)